Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.26371 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Kaicheng Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research, Education, Evaluation and Engagement Activities Center for Headache, Headache Centers of Excellence, US Department of Veterans Affairs, Ora…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, COVID-19, Migraine Disorders, Veterans. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Importance Calcitonin gene–related peptide (CGRP), a neuropeptide involved in migraine pathophysiology, is also a key neuroimmune modulator. CGRP antagonists may help mitigate the hyperinflammatory response observed in patients with COVID-19; however, findings from the literature are contradictory, and to date, no study has investigated the safety and effectiveness of CGRP antagonists against COVID-19.
Objective
To evaluate the association between CGRP monoclonal antibody (mAb) treatment and risk of SARS-CoV-2 infection and sequela hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death. Design, Setting, and Participants This retrospective cohort study analyzed the electronic health records of US veterans aged 18 to 65 years who were diagnosed with migraine disorder and were at risk of COVID-19 between January 20, 2020, and May 19, 2022. Exposure Initiation of CGRP mAbs. Main Outcomes and Measures The main outcome was cumulative incidence of SARS-CoV-2 infection. Odds of 30-day hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death were secondary outcomes.
Results
Among 8 178 652 eligible person-trials (354 294 veterans), 9992 (mean [SD] age, 46.0 [9.5] years; 53.9% male) initiated CGRP mAbs and 8 168 660 (mean [SD] age, 46.6 [10.2] years; 65.7% male) did not initiate CGRP mAbs. Over a 28-month follow-up period, 1247 initiators (12.5%) and 780 575 noninitiators (9.6%) tested positive for SARS-CoV-2. After censoring persons who deviated from treatment, the incidence was 7.4 cases per 1000 person-months among initiators and 6.9 per 1000 person-months among noninitiators. The inverse probability–weighted observational analogs of intention-to-treat and per-protocol hazard ratios were 0.95 (95% CI, 0.89-1.01) and 0.93 (95% CI, 0.86-1.02), respectively. No significant differences in the likelihood of hospitalization (odds ratio [OR], 0.93; 95% CI, 0.62-1.41), requiring supplemental oxygen (OR, 0.77; 95% CI, 0.45-1.30), use of mechanical ventilation (OR, 0.85; 95% CI, 0.26-2.84), or death (OR, 0.67; 95% CI, 0.09-5.23) were observed between CGRP mAb initiators and noninitiators who tested positive for SARS-CoV-2. Conclusions and Relevance In this cohort study, CGRP mAb treatment was not associated with positive SARS-CoV-2 test results or risk of severe COVID-19 outcomes, suggesting that CGRP mAbs may be used for migraine prevention during the COVID-19 pandemic. Given the few events of requiring supplemental oxygen, use of mechanical ventilation, and death, replication analysis in a larger sample of patients later in the course of disease is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research, Education, Evaluation and Engagement Activities Center for Headache, Headache Centers of Excellence, US Department of Veterans Affairs, Orange, Connecticut.
- Yale Center for Analytic Sciences, Yale School of Public Health, New Haven, Connecticut.
- Pain Research, Informatics, Multi-morbidities, and Education Center, VA Connecticut Healthcare System, West Haven.
- Department of Neurology, Yale School of Medicine, New Haven, Connecticut.
- Headache Center of Excellence, VA Minneapolis Health Care System, Minneapolis, Minnesota.
- Headache Center of Excellence, VA Connecticut Healthcare System, West Haven.
Förderung
- NCATS NIH HHS
Zitieren
APA
Wang, K., Fenton, B. T., Deng, Y., Anthony, S. E., Dao, V. X., Schindler, E., Lipton, R. B., Guirguis, A., Skanderson, M., Seng, E. K., & Sico, J. J. (2023). Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.26371
Vancouver
Wang K, Fenton BT, Deng Y, Anthony SE, Dao VX, Schindler E, et al. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.26371
BibTeX
@article{Wang2023,
author = {Wang, Kaicheng and Fenton, Brenda T and Deng, Yanhong and Anthony, Sarah E and Dao, Vinh X and Schindler, Emmanuelle and Lipton, Richard B and Guirguis, Alexander and Skanderson, Melissa and Seng, Elizabeth K and Sico, Jason J},
title = {Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.26371}
}
EUVIMED